Skip to content
ClinCalc Pro
Menu
Centrally-acting α2-agonist

Clonidine hydrochloride

Brand names: Catapres, Dixarit

Clonidine hydrochloride is a centrally acting antihypertensive, also used in some settings for resistant hypertension and certain off-licence indications such as menopausal flushing.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It stimulates central alpha-2 adrenoceptors, reducing sympathetic outflow from the brain to lower peripheral vascular resistance, heart rate and blood pressure.

Prescribing in practice

  • Do not stop abruptly, as sudden withdrawal can cause a dangerous rebound hypertensive crisis, so always taper the dose.
  • Sedation, dry mouth and a slow heart rate are common, and it should be used cautiously with other sedating or rate-limiting drugs.
  • Use caution in bradyarrhythmias and significant cerebrovascular or cardiovascular disease.

Monitoring

Monitor blood pressure and heart rate, with particular vigilance for rebound hypertension if treatment is interrupted.

Counselling the patient

  • Never stop this medicine suddenly; reductions must be gradual and supervised.
  • It may cause drowsiness and a dry mouth, so take care with driving until you know how it affects you.
  • Report fainting, a very slow pulse or a sudden rise in blood pressure if a dose is missed.

Evidence & guidelines

The rebound hypertension risk on abrupt withdrawal of centrally acting alpha-2 agonists is well established, and clonidine remains a recognised option for resistant hypertension in current prescribing references.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.